Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022. In Vitro: Pretreatment with desethyl KBT-3022 0.1, 0.3 and 1 mg/kg, i.v. prolongs the time required to achieve thrombotic occlusion in the femoral artery and inhibits collagen-induced platelet aggregation in whole blood ex vivo, each in a dose-dependent manner. Desethyl KBT-3022 inhibits the thrombin-induced aggregation of washed platelets in a concentration-dependent manner 1–40 μM^[1].